Scarica l'app Stockscreener
4.67
0.65%
0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$4.64
Aprire:
$4.65
Volume 24 ore:
21.20M
Relative Volume:
0.59
Capitalizzazione di mercato:
$2.43B
Reddito:
$64.60M
Utile/perdita netta:
$-377.75M
Rapporto P/E:
-3.0129
EPS:
-1.55
Flusso di cassa netto:
$-335.64M
1 W Prestazione:
+0.21%
1M Prestazione:
+11.19%
6M Prestazione:
-13.36%
1 anno Prestazione:
-27.03%
Intervallo 1D:
$4.55
$4.88
Intervallo di 1 settimana:
$4.55
$4.98
Portata 52W:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Confronta RXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.67 | 2.41B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Is Meta Stock a Buy Going Into 2026? - AOL.com
Is It Time To Reassess Recursion Pharmaceuticals (RXRX) After Recent Share Price Weakness - simplywall.st
Is Recursion Pharmaceuticals (RXRX) Pricing In Its AI Drug Discovery Ambitions? - Yahoo Finance
2 AI stocks to buy in 2026, and 1 to avoid - MSN
2 AI Stocks to Buy in 2026, and 1 to Avoid - Finviz
Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates (NASDAQ:RXRX) - Seeking Alpha
Assessing Recursion Pharmaceuticals (RXRX) Valuation After JP Morgan Update And REC-4881 Clinical Milestones - simplywall.st
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
How Recursion’s AI Drug Platform Progress And Extended Runway At Recursion Pharmaceuticals (RXRX) Has Changed Its Investment Story - simplywall.st
Recursion Pharmaceuticals patents PIKfyve inhibitors - BioWorld MedTech
How does Recursion Pharmaceuticals Inc score in quality rankingsStop Loss & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Potential Upside Amidst Biotechnology Challenges - DirectorsTalk Interviews
Market Outlook: Is Recursion Pharmaceuticals Inc stock overvalued by current metrics2025 Retail Activity & Safe Entry Momentum Tips - Bộ Nội Vụ
Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus - TechStock²
Why Recursion Pharmaceuticals Stock Is Quietly Climbing - TipRanks
Recursion Updates AI Drug Platform, Financial Outlook at JPM - TipRanks
Recursion Pharmaceuticals, Inc. Releases Updated Investor Presentation - TradingView — Track All Markets
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Will Recursion Pharmaceuticals Inc. stock benefit from infrastructure spendingStock Surge & Detailed Earnings Play Alerts - ulpravda.ru
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know - sharewise.com
Insider Sell: Blake Borgeson Sells 220,000 Shares of Recursion P - GuruFocus
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 220,000 Shares - MarketBeat
Recursion Pharmaceuticals Insider Sold Shares Worth $959,200, According to a Recent SEC Filing - MarketScreener
Can Recursion Pharmaceuticals Inc. stock surprise with earnings upsideJuly 2025 Macro Moves & Free Community Consensus Stock Picks - ulpravda.ru
Aug Setups: How Recursion Pharmaceuticals Inc. stock performs after earningsJuly 2025 Opening Moves & Safe Entry Momentum Tips - ulpravda.ru
Recursion pharma director Gibson sells $170k in shares By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates - Finviz
Recursion’s Stock Surge: An Opportunity? - StocksToTrade
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week’s Business Updates - Insider Monkey
Recursion Pharmaceuticals Stock Surges: What’s Happening? - timothysykes.com
RXRX Stock’s Impressive Surge: A Closer Look - timothysykes.com
Why Recursion Pharmaceuticals (RXRX) Is Up 10.7% After Positive REC-4881 Trial Data And Rising Analyst Focus - simplywall.st
Recursion Pharmaceuticals Inc Stock Analysis and ForecastLow Risk Investment Ideas & AI-Based Insights for Consistent Profits - earlytimes.in
Recursion Pharmaceuticals, Inc. (RXRX) Investor Outlook: Uncovering a 60% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. - AOL.com
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) Mispriced After Volatile Share Performance And Ongoing Tech Partnerships - simplywall.st
Here’s what JP Morgan thinks about Recursion Pharmaceuticals (RXRX) - MSN
JPMorgan boosts rating on Recursion Pharmaceuticals (RXRX) amid AI-driven drug pipeline - MSN
Should J.P. Morgan’s REC-4881 Upgrade and TUPELO Data Require Action From Recursion (RXRX) Investors? - Yahoo Finance
Recursion Pharmaceuticals (RXRX): Assessing Valuation After New Activist Investor Filings With the SEC - simplywall.st
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Insider Trading - Quiver Quantitative
Here’s What J.P. Morgan Thinks About Recursion Pharmaceuticals (RXRX) - Insider Monkey
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline - Finviz
Bank Pictet & Cie Europe AG Acquires Shares of 1,630,000 Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals reports positive Phase 1b/2 TUPELO trial results, validating AI-driven therapy for FAP - MSN
Cathie Wood’s ARK Investment buys 755K shares of Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) - Yahoo Finance
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Recursion Pharmaceuticals Inc Azioni (RXRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gibson Christopher | Director |
Jan 05 '26 |
Sale |
4.25 |
40,000 |
170,000 |
933,839 |
4.73%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):